Drugs / BI 706321
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05183360 | Feb → Aug 2022 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT04714073 | Feb → Apr 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03971695 | Jun 2019 → Dec 2020 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04978493 | Dec 2021 → Jul 2024 | Crohn disease | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 706321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03971695 ↗ |
| Route | Oral | “taken orally with 240 milliliter (mL) of water” NCT03971695 ↗ |